Implant Sciences Corporation announced Thursday it has won a patent from the U.S. Patent and Trademark Office (# 8,353,223), called the “Trace Particle Collection System.” With this patent Implant Sciences now hold 16 patents in total in the U.S., all to do with the company’s business, which include high technology systems and sensors for homeland security and defense markets. This patent is for a trace particle collection system that is used to collect and remove trace particles that are bound to a target surface.
“The recent TSA approval of our QS-B220 validates the efficacy of our groundbreaking technology and will help us solidify our position in the market,” said Dr. Bill McGann, COO for Implant Sciences.
As a top developer of safety, security and defense-use products, Impact can use this patent now to ensure its technologies made for commercial explosives, narcotics trace detection systems, and such as portable explosives trace detectors, as well other various products and uses, are legally protected.
Trace detection can help in sample harvesting and transport as well, which is the next step for Implant, says the company’s vice president of technology Todd Silvestri. “This invention is an example of Implant Sciences looking beyond traditional trace detection methods to enhance sample harvesting and transport,” said Silvestri. “In trace detection, sample collection is just as important as analysis. Our research team is constantly expanding our technological capabilities.”
Implant is now currently the only company with product approval from the US Transportation Security Administration for its ETD products (explosives trace detection), as well as the sole American-owned leader in the field.
McGann added that this patent is undeniable proof that “Implant Sciences continues to innovate the next generation of explosives trace detection systems.”
Edited by Amanda Ciccatelli